BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 20332326)

  • 1. Cyclooxygenase-2 genetic variants are associated with survival in unresectable locally advanced non-small cell lung cancer.
    Bi N; Yang M; Zhang L; Chen X; Ji W; Ou G; Lin D; Wang L
    Clin Cancer Res; 2010 Apr; 16(8):2383-90. PubMed ID: 20332326
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Polymorphisms in the FAS and FASL genes and survival of early stage non-small cell lung cancer.
    Park JY; Lee WK; Jung DK; Choi JE; Park TI; Lee EB; Cho S; Park JY; Cha SI; Kim CH; Kam S; Jung TH; Jheon S
    Clin Cancer Res; 2009 Mar; 15(5):1794-800. PubMed ID: 19240174
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of EGFR SNPs in survival of advanced lung adenocarcinoma patients treated with Gefitinib.
    Zhang L; Yuan X; Chen Y; Du XJ; Yu S; Yang M
    Gene; 2013 Mar; 517(1):60-4. PubMed ID: 23313300
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of vascular endothelial growth factor polymorphisms on survival in advanced-stage non-small-cell lung cancer.
    Masago K; Fujita S; Kim YH; Hatachi Y; Fukuhara A; Nagai H; Irisa K; Ichikawa M; Mio T; Mishima M
    Cancer Sci; 2009 Oct; 100(10):1917-22. PubMed ID: 19594543
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The prognostic significance of lymphovascular invasion on biopsy specimens in lung cancer treated with definitive chemoradiotherapy.
    Massabeau C; Filleron T; Wakil G; Rouquette I; Bachaud JM; Leguellec S; Delisle MB; Toulas C; Mazieres J; Cohen-Jonathan Moyal E
    Clin Lung Cancer; 2012 Jan; 13(1):59-67. PubMed ID: 21856239
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Polymorphisms of vitamin D receptor and survival in early-stage non-small cell lung cancer patients.
    Zhou W; Heist RS; Liu G; Neuberg DS; Asomaning K; Su L; Wain JC; Lynch TJ; Giovannucci E; Christiani DC
    Cancer Epidemiol Biomarkers Prev; 2006 Nov; 15(11):2239-45. PubMed ID: 17119052
    [TBL] [Abstract][Full Text] [Related]  

  • 7. VEGF polymorphisms and survival in early-stage non-small-cell lung cancer.
    Heist RS; Zhai R; Liu G; Zhou W; Lin X; Su L; Asomaning K; Lynch TJ; Wain JC; Christiani DC
    J Clin Oncol; 2008 Feb; 26(6):856-62. PubMed ID: 18281657
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized phase II and pharmacogenetic study of pemetrexed compared with pemetrexed plus carboplatin in pretreated patients with advanced non-small-cell lung cancer.
    Smit EF; Burgers SA; Biesma B; Smit HJ; Eppinga P; Dingemans AM; Joerger M; Schellens JH; Vincent A; van Zandwijk N; Groen HJ
    J Clin Oncol; 2009 Apr; 27(12):2038-45. PubMed ID: 19307503
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative survival in patients with postresection recurrent versus newly diagnosed non-small-cell lung cancer treated with radiotherapy.
    Cai XW; Xu LY; Wang L; Hayman JA; Chang AC; Pickens A; Cease KB; Orringer MB; Kong FM
    Int J Radiat Oncol Biol Phys; 2010 Mar; 76(4):1100-5. PubMed ID: 19540063
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Polymorphisms in EGFR and VEGF contribute to non-small-cell lung cancer survival in a Chinese population.
    Dong J; Dai J; Shu Y; Pan S; Xu L; Chen W; Wang Y; Jin G; Ma H; Zhang M; Hu Z; Shen H
    Carcinogenesis; 2010 Jun; 31(6):1080-6. PubMed ID: 20400478
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The 3' UTR IGF2R-A2/B2 variant is associated with increased tumor growth and advanced stages in non-small cell lung cancer.
    Kotsinas A; Evangelou K; Sideridou M; Kotzamanis G; Constantinides C; Zavras AI; Douglass CW; Papavassiliou AG; Gorgoulis VG
    Cancer Lett; 2008 Feb; 259(2):177-85. PubMed ID: 18037232
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vascular endothelial growth factor receptor 2 gene polymorphisms as predictors for tumor recurrence and overall survival in non-small-cell lung cancer.
    Uzunoglu FG; Kaufmann C; Wikman H; Güngör C; Bohn BA; Nentwich MF; Reeh M; Pantel K; Bockhorn M; Kutup A; Mann O; Izbicki JR; Vashist YK
    Ann Surg Oncol; 2012 Jul; 19(7):2159-68. PubMed ID: 22395975
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical significance of ERCC2 haplotype-tagging single nucleotide polymorphisms in patients with unresectable non-small cell lung cancer treated with first-line platinum-based chemotherapy.
    Kim SH; Lee GW; Lee MJ; Cho YJ; Jeong YY; Kim HC; Lee JD; Hwang YS; Kim IS; Lee S; Oh SY
    Lung Cancer; 2012 Sep; 77(3):578-84. PubMed ID: 22608006
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Survival of patients with advanced non-small-cell lung cancer at Ubon Ratchathani Cancer Center, Thailand.
    Srisam-Ang K; Podhipak A; Narksawat K; Supaattagorn P; Tipayamongkholgul M
    Southeast Asian J Trop Med Public Health; 2005 Jul; 36(4):994-1006. PubMed ID: 16295558
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of outcomes for patients with unresectable, locally advanced non-small-cell lung cancer treated with induction chemotherapy followed by concurrent chemoradiation vs. concurrent chemoradiation alone.
    Huang EH; Liao Z; Cox JD; Guerrero TM; Chang JY; Jeter M; Borghero Y; Wei X; Fossella F; Herbst RS; Blumenschein GR; Moran C; Allen PK; Komaki R
    Int J Radiat Oncol Biol Phys; 2007 Jul; 68(3):779-85. PubMed ID: 17418967
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Platelet 12-lipoxygenase Arg261Gln polymorphism: functional characterization and association with risk of esophageal squamous cell carcinoma in combination with COX-2 polymorphisms.
    Guo Y; Zhang X; Tan W; Miao X; Sun T; Zhao D; Lin D
    Pharmacogenet Genomics; 2007 Mar; 17(3):197-205. PubMed ID: 17460548
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gender differences in non-small-cell lung cancer survival: an analysis of 4,618 patients diagnosed between 1997 and 2002.
    Visbal AL; Williams BA; Nichols FC; Marks RS; Jett JR; Aubry MC; Edell ES; Wampfler JA; Molina JR; Yang P
    Ann Thorac Surg; 2004 Jul; 78(1):209-15; discussion 215. PubMed ID: 15223430
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase I clinical trial of thoracic radiotherapy and concurrent celecoxib for patients with unfavorable performance status inoperable/unresectable non-small cell lung cancer.
    Liao Z; Komaki R; Milas L; Yuan C; Kies M; Chang JY; Jeter M; Guerrero T; Blumenschien G; Smith CM; Fossella F; Brown B; Cox JD
    Clin Cancer Res; 2005 May; 11(9):3342-8. PubMed ID: 15867233
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Concurrent versus sequential chemoradiotherapy with cisplatin and vinorelbine in locally advanced non-small cell lung cancer: a randomized study.
    Zatloukal P; Petruzelka L; Zemanova M; Havel L; Janku F; Judas L; Kubik A; Krepela E; Fiala P; Pecen L
    Lung Cancer; 2004 Oct; 46(1):87-98. PubMed ID: 15364136
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Prognosis of locally advanced non small cell lung cancer treated with three dimentional conformal radiotherapy].
    Zhu XZ; Wang LH; Ou GF; Zhou ZM; Chen DF; Xiao ZF; Feng QF; Zhang HX; Wang M; Yin WB
    Zhonghua Zhong Liu Za Zhi; 2007 Oct; 29(10):748-53. PubMed ID: 18396686
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.